Veru Inc. · NASDAQ:VERU

Veru — Obesity Week 2026

15 slides from Veru's conference presentation, Nov 16, 2026

  1. Slide 1: Enobosarm in Older Patients (≥65) with Obesity on Semaglutide

    Enobosarm in Older Patients (≥65 years) with Obesity on Semaglutide: Quality Weight Loss & Better Physical Function Phase 2 QUALITY Clinical Study Post-hoc Subset Analysis K. Gary Barnette, PhD, CSO, Veru Inc. Obesity Week 16 November 2026 VERU INC. | NASDAQ: VERU MIAMI, FLORIDA

  2. Slide 2: Weight loss on GLP-1 therapy can cost older adults function

    Weight loss on GLP-1 therapy can cost older adults function Lean mass is lost Older adults have the least Stairs test real-world reserve function Part of the weight lost on semaglutide Losing muscle at 65+ puts mobility Time to climb, and power generated, is lean mass, not just fat. and independence

  3. Slide 3: Completed Phase 2b QUALITY clinical trial study in 2025

    PHASE 2b QUALITY TRIAL Completed Phase 2b QUALITY clinical trial study in 2025 Evaluated enobosarm in 168 patients with obesity Active weight loss Maintenance Primary endpoint (16 weeks) Sample size calculation Lean body mass measured by DXA scan Enobosarm 6 mg PO • n=168 patients Enobosarm 6 mg PO

  4. Slide 4: Stair climb test

    PHYSICAL FUNCTION Stair climb test1,2 Stair climb power (Watts)= (Body weight + load carried (kg)) X 9.81 m/s2 X total stair rise (m) time (s) 1. Travison TG et al. J Geront A Biol Sci Med Sci 10:1090, 2011| 2 Gagliano-Juca T. et al. J Gerontol A Biol Sci Med Sci 75:1167-1175, 2020

  5. Slide 5: Older patients started slower and weaker on the stairs

    BASELINE STAIR CLIMB BY AGE FROM PHASE 2b QUALITY CLINICAL STUDY Older patients started slower and weaker on the stairs 60 to <65 65 to <70 ≥70 n=72 n=57 n=35 Stair climb time Stair climb time Stair climb time 5.58 (2.34) s 6.24 (2.18) s 6.90 (4.16) s Stair climb power Stair climb power Stair climb

  6. Slide 6: Post-hoc Analysis: Patients 65 and older, 3 mg vs placebo, at Day 112

    Methods Post-hoc Analysis: Patients 65 and older, 3 mg vs placebo, at Day 112 Item Detail Trial V2000101 Phase 2b, Double-Blind, Randomized, Placebo-Controlled QUALITY Study Treatment All subjects received semaglutide in accordance with the approved prescribing instructions Comparison (post-hoc anal

  7. Slide 7: Age ≥65: Enobosarm 3 mg kept lean mass while losing the same fat

    BODY COMPOSITION · DAY 112 Age ≥65: Enobosarm 3 mg kept lean mass while losing the same fat as placebo in this short 16 week-study Total lean mass Total fat mass Enobosarm 3 mg +0.3 kg Enobosarm 3 mg −3.5 kg Placebo −2.0 kg Placebo −3.4 kg Adjusted difference = +2.3 kg on 3 mg, p=0.0001 No differenc

  8. Slide 8: Age ≥65: On enobosarm 3 mg, patients climbed 15% faster than baseline

    STAIR CLIMB TIME · DAY 112 Age ≥65: On enobosarm 3 mg, patients climbed 15% faster than baseline % faster than baseline (ANCOVA LS mean, adjusted for baseline time) Enobosarm 3 mg 15.1% 24x difference in time ∆ (relative difference) Placebo 0.6% Difference, 3 mg − placebo Median % change Change in s

  9. Slide 9: Age ≥65: 3 mg patients gained power despite losing weight

    STAIR CLIMB POWER · DAY 112 Age ≥65: 3 mg patients gained power despite losing weight Change in stair climb power, watts (ANCOVA LS mean, adjusted for baseline) Enobosarm 3 mg +38.4 W 29x difference in power ∆ (relative difference) Placebo +1.3 W Difference, 3 mg − placebo Median change in watts Med

  10. Slide 10: Age ≥65: Far fewer 3 mg patients lost stair function

    RESPONDER ANALYSIS · DAY 112 Age ≥65: Far fewer 3 mg patients lost stair function Got slower (any increase in time) Lost ≥10% of stair power 3 mg 12% (3/26) 3 mg 0% (0/26) Placebo 42% Placebo 42% Placebo 11/26. Fisher p=0.027; adjusted OR 0.17, p=0.021 Placebo 11/26. Fisher p<0.001 Age ≥65; implausi

  11. Slide 11: Physical function benefit with enobosarm appears greater with age

    EFFECT BY AGE · ALL AGES, 3 MG VS PLACEBO The physical function benefit with enobosarm treatment appears to be greater with age Age n per arm Stair time, 3 mg − placebo Lost ≥10% power, 3 mg vs placebo 65–69 17 / 17 −8.4% 0% vs 41% (p=0.007) 70 and over 9/9 −24.7% 0% vs 44% (p=0.08) Amount enobosarm

  12. Slide 12: Conclusions

    CONCLUSIONS Question 1 • Does rapid weight loss (with GLP-1 therapy) cause clinically relevant reduction in physical function in older patients (≥65 years of age)? Answer • Yes, the following observations are made: • While you would expect patients that lose weight to go up the steps faster, 42% of

  13. Slide 13: Conclusions

    CONCLUSIONS Question 2 • Does enobosarm 3 mg preserve physical function (stair climb) in older patients (≥65 years of age) over 16 weeks? Answer • Yes, the following observations are made: • The proportion of subjects that were slower going up the stairs was significantly lower in the enobosarm grou

  14. Slide 14: Phase 2b PLATEAU clinical study design - Fully enrolled

    TRIAL DESIGN Phase 2b PLATEAU clinical study design* - Fully enrolled Double blind study to evaluate enobosarm 3 mg on total body weight, body composition (DEXA), physical function, and safety in 239 older patients with obesity taking semaglutide for weight reduction Study duration is 68-week, Doubl

  15. Slide 15: < o = rt 0) me} &

    < o = rt 0) me} & 7

Veru — Obesity Week 2026 on 6ix